Guidance for Industry on Tobacco Health Document Submission; Availability, 20606-20607 [2010-9134]
Download as PDF
20606
Federal Register / Vol. 75, No. 75 / Tuesday, April 20, 2010 / Notices
Dated: April 14, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
[FR Doc. 2010–8977 Filed 4–19–10; 8:45 am]
The Agricultural Health Study: A
Prospective Cohort Study of Cancer
and Other Disease Among Men and
Women in Agriculture (NCI);
Correction Notice
BILLING CODE 4160–01–S
The Federal Register notice published
on March 3, 2010 (75 FR 9902)
announcing the proposed collection and
comment request for the project titled,
‘‘The Agricultural Health Study: A
Prospective Cohort Study of Cancer and
Other Disease Among Men and Women
in Agriculture (NCI)’’ was submitted
with errors. The burden table did not
take into account the time related to
complete the Phase III CATI as well as
several telephone calls to schedule
appointments and to follow up with
instructions regarding the biospecimens
collection. The corrected annual
reporting burden is as follows:
TABLE A.12–1—ESTIMATES OF ANNUAL BURDEN HOURS
Estimated annual
number of respondents
Frequency of response
Average time per
response minutes/hour
Phase III Telephone Interview
& Buccal Cell Scripts.
Phase III CATI ..........................
150
1
5/60 (0.083)
12.50
150
1
35/60 (0.583)
87.50
Phase III Buccal Cell Reminder, Missing or Damaged
Scripts.
BEEA CATI Screener ...............
BEEA Home Visit CAPI, Blood,
& Urine x 1.
BEEA Schedule Home Visit
Script.
BEEA Home Visit CAPI, Blood,
& Urine x 3.
150
1
5/60 (0.083)
12.50
960
310
1
1
20/60 (0.33)
20/60 (0.33)
320.00
5.17
10
3
5/60 (0.33)
2.50
10
3
≤ 20/60 (0.33)
10.00
...................................................
1740
............................
............................
450.17
Type of respondent
Instrument
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators, Spouses,
Commercial Applicators.
Private Applicators ....................
Private Applicators ....................
Private Applicators ....................
Private Applicators ....................
Total ...................................
Dated: April 14, 2010.
Vivian Horovitch-Kelley,
NCI Project Clearance Liaison, National
Institutes of Health.
DATES: Submit written or electronic
comments on this guidance at any time.
General comments on agency guidance
documents are welcome at any time.
[FR Doc. 2010–9098 Filed 4–19–10; 8:45 am]
Submit written requests for
single copies of the guidance document
entitled ‘‘Tobacco Health Document
Submission’’ to the Center for Tobacco
Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850–3229. Send one
self-addressed adhesive label to assist
that office in processing your request or
include a fax number to which the draft
guidance document may be sent. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance document.
Submit electronic comments to https://
www.regulations.gov. Submit written
comments on the guidance to the
Division of Dockets Management (HFA–
305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
ADDRESSES:
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–D–0600]
Guidance for Industry on Tobacco
Health Document Submission;
Availability
AGENCY:
Food and Drug Administration,
HHS.
erowe on DSK5CLS3C1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance entitled
‘‘Tobacco Health Document
Submission.’’ The guidance document is
intended to assist persons making
certain document submissions to FDA
under the Family Smoking Prevention
and Tobacco Control Act (Tobacco
Control Act).
VerDate Nov<24>2008
14:55 Apr 19, 2010
Jkt 220001
FOR FURTHER INFORMATION CONTACT: Beth
Buckler, Center for Tobacco Products,
Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850–
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
Annual burden
hours
3229, 1–877–287–1373,
Beth.Buckler@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of December
28, 2009 (74 FR 68629), FDA announced
the availability of a draft guidance
entitled ‘‘Tobacco Health Document
Submission.’’ The agency considered
received comments as it finalized this
guidance. The guidance document is
intended to assist persons making
certain document submissions to FDA
under the Tobacco Control Act (Public
Law 111–31).
The Tobacco Control Act amended
the Federal Food, Drug, and Cosmetic
Act (the act) (21 U.S.C. 301 et seq.) by,
among other things, adding a new
chapter granting FDA important new
authority to regulate the manufacture,
marketing, and distribution of tobacco
products to protect the public health
generally and to reduce tobacco use by
minors. Section 904(a)(4) of the act, as
amended by the Tobacco Control Act,
requires each tobacco product
manufacturer or importer, or agent
thereof, to submit all documents
developed after June 22, 2009 ‘‘that
relate to health, toxicological,
E:\FR\FM\20APN1.SGM
20APN1
Federal Register / Vol. 75, No. 75 / Tuesday, April 20, 2010 / Notices
behavioral, or physiologic effects of
current or future tobacco products, their
constituents (including smoke
constituents), ingredients, components,
and additives.’’ Information required
under section 904(a)(4) of the act must
be submitted to FDA beginning
December 22, 2009. FDA recognizes the
challenges associated with the
collection, review, organization, and
production of documents. We also
recognize that additional time may be
necessary for the production of
documents in a digital format, which
FDA strongly encourages in order to
improve the management and
accessibility of submitted documents.
Therefore, FDA does not intend to
enforce the December 22, 2009, deadline
provided you submit by April 30, 2010,
all documents described in section
904(a)(4) of the act developed between
June 22, 2009 and December 31, 2009.
II. Significance of Guidance
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on ‘‘Tobacco Health
Document Submission.’’ It does not
create or confer any rights for or on any
person and does not operate to bind
FDA or the public. An alternative
approach may be used if such approach
satisfies the requirements of the
applicable statute and regulations.
erowe on DSK5CLS3C1PROD with NOTICES
III. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. The guidance
document and received comments may
be seen in the Division of Dockets
Management between 9 a.m. and 4 p.m.,
Monday through Friday.
IV. Paperwork Reduction Act of 1995
This guidance contains information
collection provisions that are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collection(s) of information
in this guidance was approved under
OMB control number 0910–0654.
V. Electronic Access
An electronic version of the guidance
document is available on the Internet at
https://www.regulations.gov and https://
VerDate Nov<24>2008
14:55 Apr 19, 2010
Jkt 220001
www.fda.gov/TobaccoProducts/
GuidanceComplianceRegulatory
Information/default.htm.
Dated: April 15, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010–9134 Filed 4–16–10; 11:15 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Sensory.
Date: May 4–5, 2010.
Time: 7 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–BST
Consolidated: Member Conflict.
Date: May 6, 2010.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ping Fan, MD, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5154,
MSC 7840, Bethesda, MD 20892, 301–408–
9971, fanp@csr.nih.gov.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
20607
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Bioengineering Sciences and
Technologies.
Date: May 7, 2010.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Ping Fan, MD, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5154,
MSC 7840, Bethesda, MD 20892, 301–408–
9971, fanp@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflicts: Clinical and Health Services
Research.
Date: May 18, 2010.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Sand Key Resort, 1160
Gulf Boulevard, Clearwater Beach, FL 33767.
Contact Person: Jacinta Bronte-Tinkew,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3164,
MSC 7770, Bethesda, MD 20892, (301) 435–
1503, brontetinkewjm@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Psychosocial Risk and Disease Prevention
Study Section.
Date: May 24–25, 2010.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott, 1960–A
Chain Bridge Road, Mclean, VA 22102.
Contact Person: Martha Faraday, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3110,
MSC 7808, Bethesda, MD 20892, 301–435–
3575, faradaym@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Neurobiology of
Learning and Memory Study Section.
Date: May 26, 2010.
Time: 8:30 .a.m to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Washington Plaza Hotel, 10 Thomas
Circle, NW., Washington, DC 20005.
Contact Person: Bernard F. Driscoll, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5184,
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov.
Name of Committee: Brain Disorders and
Clinical Neuroscience Integrated Review
Group; Neural Basis of Psychopathology,
Addictions and Sleep Disorders Study
Section.
Date: May 27–28, 2010.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites Hotel, 1250 22nd
Street, NW., Washington, DC 20037.
E:\FR\FM\20APN1.SGM
20APN1
Agencies
[Federal Register Volume 75, Number 75 (Tuesday, April 20, 2010)]
[Notices]
[Pages 20606-20607]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9134]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-D-0600]
Guidance for Industry on Tobacco Health Document Submission;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance entitled ``Tobacco Health Document
Submission.'' The guidance document is intended to assist persons
making certain document submissions to FDA under the Family Smoking
Prevention and Tobacco Control Act (Tobacco Control Act).
DATES: Submit written or electronic comments on this guidance at any
time. General comments on agency guidance documents are welcome at any
time.
ADDRESSES: Submit written requests for single copies of the guidance
document entitled ``Tobacco Health Document Submission'' to the Center
for Tobacco Products, Food and Drug Administration, 9200 Corporate
Blvd., Rockville, MD 20850-3229. Send one self-addressed adhesive label
to assist that office in processing your request or include a fax
number to which the draft guidance document may be sent. See the
SUPPLEMENTARY INFORMATION section for information on electronic access
to the guidance document.
Submit electronic comments to https://www.regulations.gov. Submit
written comments on the guidance to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. Identify comments with the docket number found in
brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Beth Buckler, Center for Tobacco
Products, Food and Drug Administration, 9200 Corporate Blvd.,
Rockville, MD 20850-3229, 1-877-287-1373, Beth.Buckler@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of December 28, 2009 (74 FR 68629), FDA
announced the availability of a draft guidance entitled ``Tobacco
Health Document Submission.'' The agency considered received comments
as it finalized this guidance. The guidance document is intended to
assist persons making certain document submissions to FDA under the
Tobacco Control Act (Public Law 111-31).
The Tobacco Control Act amended the Federal Food, Drug, and
Cosmetic Act (the act) (21 U.S.C. 301 et seq.) by, among other things,
adding a new chapter granting FDA important new authority to regulate
the manufacture, marketing, and distribution of tobacco products to
protect the public health generally and to reduce tobacco use by
minors. Section 904(a)(4) of the act, as amended by the Tobacco Control
Act, requires each tobacco product manufacturer or importer, or agent
thereof, to submit all documents developed after June 22, 2009 ``that
relate to health, toxicological,
[[Page 20607]]
behavioral, or physiologic effects of current or future tobacco
products, their constituents (including smoke constituents),
ingredients, components, and additives.'' Information required under
section 904(a)(4) of the act must be submitted to FDA beginning
December 22, 2009. FDA recognizes the challenges associated with the
collection, review, organization, and production of documents. We also
recognize that additional time may be necessary for the production of
documents in a digital format, which FDA strongly encourages in order
to improve the management and accessibility of submitted documents.
Therefore, FDA does not intend to enforce the December 22, 2009,
deadline provided you submit by April 30, 2010, all documents described
in section 904(a)(4) of the act developed between June 22, 2009 and
December 31, 2009.
II. Significance of Guidance
This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
agency's current thinking on ``Tobacco Health Document Submission.'' It
does not create or confer any rights for or on any person and does not
operate to bind FDA or the public. An alternative approach may be used
if such approach satisfies the requirements of the applicable statute
and regulations.
III. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. The guidance document and received
comments may be seen in the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
IV. Paperwork Reduction Act of 1995
This guidance contains information collection provisions that are
subject to review by the Office of Management and Budget (OMB) under
the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collection(s) of information in this guidance was approved under OMB
control number 0910-0654.
V. Electronic Access
An electronic version of the guidance document is available on the
Internet at https://www.regulations.gov and https://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/default.htm.
Dated: April 15, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-9134 Filed 4-16-10; 11:15 am]
BILLING CODE 4160-01-S